Literature DB >> 29302241

Management of prostate cancer: NYU Case of the Month, July 2017.

Samir S Taneja1.   

Abstract

Entities:  

Year:  2017        PMID： 29302241      PMCID： PMC5737345          DOI： 10.3909/riu0771

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


× No keyword cloud information.
  41 in total

1.  Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.

Authors:  Win Shun Lai; Jennifer B Gordetsky; John V Thomas; Jeffrey W Nix; Soroush Rais-Bahrami
Journal:  Cancer       Date:  2017-01-31       Impact factor: 6.860

Review 2.  The role of MRI in prostate cancer diagnosis and management.

Authors:  Neil Mendhiratta; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Future Oncol       Date:  2016-09-19       Impact factor: 3.404

Review 3.  AUA Policy Statement on the Use of Multiparametric Magnetic Resonance Imaging in the Diagnosis, Staging and Management of Prostate Cancer.

Authors:  Pat F Fulgham; Daniel B Rukstalis; Ismail Baris Turkbey; Jonathan N Rubenstein; Samir Taneja; Peter R Carroll; Peter A Pinto; Marc A Bjurlin; Scott Eggener
Journal:  J Urol       Date:  2017-05-05       Impact factor: 7.450

Review 4.  Genomic Predictors of Outcome in Prostate Cancer.

Authors:  Peter J Boström; Anders S Bjartell; James W F Catto; Scott E Eggener; Hans Lilja; Stacy Loeb; Jack Schalken; Thorsten Schlomm; Matthew R Cooperberg
Journal:  Eur Urol       Date:  2015-04-23       Impact factor: 20.096

Review 5.  Active surveillance for prostate cancer: current evidence and contemporary state of practice.

Authors:  Jeffrey J Tosoian; H Ballentine Carter; Abbey Lepor; Stacy Loeb
Journal:  Nat Rev Urol       Date:  2016-03-08       Impact factor: 14.432

Review 6.  Using multiparametric MRI to 'personalize' biopsy for men.

Authors:  Neil Mendhiratta; Xiaosong Meng; Samir S Taneja
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

7.  Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.

Authors:  Stacy Loeb; Anders Berglund; Pär Stattin
Journal:  J Urol       Date:  2013-05-30       Impact factor: 7.450

8.  Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort.

Authors:  Matthew R Cooperberg; Jeffry P Simko; Janet E Cowan; Julia E Reid; Azita Djalilvand; Satish Bhatnagar; Alexander Gutin; Jerry S Lanchbury; Gregory P Swanson; Steven Stone; Peter R Carroll
Journal:  J Clin Oncol       Date:  2013-03-04       Impact factor: 44.544

9.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort.

Authors:  J Cuzick; D M Berney; G Fisher; D Mesher; H Møller; J E Reid; M Perry; J Park; A Younus; A Gutin; C S Foster; P Scardino; J S Lanchbury; S Stone
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

10.  Concern for overtreatment using the AUA/ASTRO guideline on adjuvant radiotherapy after radical prostatectomy.

Authors:  Jung Hun Kang; Yun-Sok Ha; Sung Kim; Jihyeong Yu; Neal Patel; Jaspreet S Parihar; Amirali Hassanzadeh Salmasi; Wun-Jae Kim; Isaac Yi Kim
Journal:  BMC Urol       Date:  2014-04-07       Impact factor: 2.264
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.